BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 24678876)

  • 21. Molecular mechanisms of selective estrogen receptor modulator activity in human breast cancer cells: identification of novel nuclear cofactors of antiestrogen-ERα complexes by interaction proteomics.
    Cirillo F; Nassa G; Tarallo R; Stellato C; De Filippo MR; Ambrosino C; Baumann M; Nyman TA; Weisz A
    J Proteome Res; 2013 Jan; 12(1):421-31. PubMed ID: 23170835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estrogen receptor α attenuates therapeutic efficacy of paclitaxel on breast xenograft tumors.
    Chang J; Sui M; Fan W
    Breast Cancer Res Treat; 2012 Aug; 134(3):969-80. PubMed ID: 22374518
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response.
    Bayliss J; Hilger A; Vishnu P; Diehl K; El-Ashry D
    Clin Cancer Res; 2007 Dec; 13(23):7029-36. PubMed ID: 18056179
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer.
    Ito T; Kamijo S; Izumi H; Kohno K; Amano J; Ito K
    Breast Cancer Res Treat; 2012 May; 133(1):145-59. PubMed ID: 21863258
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of antiestrogens and aromatase inhibitor on basal growth of the human breast cancer cell line MCF-7 in serum-free medium.
    Jensen J; Kitlen JW; Briand P; Labrie F; Lykkesfeldt AE
    J Steroid Biochem Mol Biol; 2003 Mar; 84(4):469-78. PubMed ID: 12732292
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of Antiestrogen-Promoted Pro-Survival Autophagy and Tamoxifen Resistance in Breast Cancer through Vitamin D Receptor.
    Li Y; Cook KL; Yu W; Jin L; Bouker KB; Clarke R; Hilakivi-Clarke L
    Nutrients; 2021 May; 13(5):. PubMed ID: 34069442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiestrogen potentiation of antiproliferative effects of vitamin D3 analogues in breast cancer cells.
    Love-Schimenti CD; Gibson DF; Ratnam AV; Bikle DD
    Cancer Res; 1996 Jun; 56(12):2789-94. PubMed ID: 8665515
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.
    Yang W; Hosford SR; Dillon LM; Shee K; Liu SC; Bean JR; Salphati L; Pang J; Zhang X; Nannini MA; Demidenko E; Bates D; Lewis LD; Marotti JD; Eastman AR; Miller TW
    Clin Cancer Res; 2016 May; 22(9):2250-60. PubMed ID: 26733612
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiestrogen-resistant subclones of MCF-7 human breast cancer cells are derived from a common monoclonal drug-resistant progenitor.
    Coser KR; Wittner BS; Rosenthal NF; Collins SC; Melas A; Smith SL; Mahoney CJ; Shioda K; Isselbacher KJ; Ramaswamy S; Shioda T
    Proc Natl Acad Sci U S A; 2009 Aug; 106(34):14536-41. PubMed ID: 19706540
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of Antiestrogen-Bound Estrogen Receptor α Interactomes in Hormone-Responsive Human Breast Cancer Cell Nuclei.
    Gigantino V; Salvati A; Giurato G; Palumbo D; Strianese O; Rizzo F; Tarallo R; Nyman TA; Weisz A; Nassa G
    Proteomics; 2020 Oct; 20(19-20):e2000135. PubMed ID: 32865868
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of estrogen receptor (ER) alpha in insulin-like growth factor (IGF)-I-induced responses in MCF-7 breast cancer cells.
    Zhang S; Li X; Burghardt R; Smith R; Safe SH
    J Mol Endocrinol; 2005 Dec; 35(3):433-47. PubMed ID: 16326831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estrogen-dependent sushi domain containing 3 regulates cytoskeleton organization and migration in breast cancer cells.
    Moy I; Todorović V; Dubash AD; Coon JS; Parker JB; Buranapramest M; Huang CC; Zhao H; Green KJ; Bulun SE
    Oncogene; 2015 Jan; 34(3):323-33. PubMed ID: 24413080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ.
    Mishra AK; Abrahamsson A; Dabrosin C
    Oncotarget; 2016 Aug; 7(35):56876-56888. PubMed ID: 27486755
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression and regulation of Cyr61 in human breast cancer cell lines.
    Tsai MS; Bogart DF; Li P; Mehmi I; Lupu R
    Oncogene; 2002 Jan; 21(6):964-73. PubMed ID: 11840342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms of estrogen receptor antagonism toward p53 and its implications in breast cancer therapeutic response and stem cell regulation.
    Konduri SD; Medisetty R; Liu W; Kaipparettu BA; Srivastava P; Brauch H; Fritz P; Swetzig WM; Gardner AE; Khan SA; Das GM
    Proc Natl Acad Sci U S A; 2010 Aug; 107(34):15081-6. PubMed ID: 20696891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Calcitriol down-regulates human ether a go-go 1 potassium channel expression in cervical cancer cells.
    Avila E; García-Becerra R; Rodríguez-Rasgado JA; Díaz L; Ordaz-Rosado D; Zügel U; Steinmeyer A; Barrera D; Halhali A; Larrea F; Camacho J
    Anticancer Res; 2010 Jul; 30(7):2667-72. PubMed ID: 20682996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
    Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
    Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Arsenic induces functional re-expression of estrogen receptor α by demethylation of DNA in estrogen receptor-negative human breast cancer.
    Du J; Zhou N; Liu H; Jiang F; Wang Y; Hu C; Qi H; Zhong C; Wang X; Li Z
    PLoS One; 2012; 7(4):e35957. PubMed ID: 22558281
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resistance to different antiestrogens is caused by different multi-factorial changes and is associated with reduced expression of IGF receptor Ialpha.
    Brockdorff BL; Heiberg I; Lykkesfeldt AE
    Endocr Relat Cancer; 2003 Dec; 10(4):579-90. PubMed ID: 14713268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resistance to antiestrogen arzoxifene is mediated by overexpression of cyclin D1.
    Zwart W; Rondaij M; Jalink K; Sharp ZD; Mancini MA; Neefjes J; Michalides R
    Mol Endocrinol; 2009 Sep; 23(9):1335-45. PubMed ID: 19477949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.